

A new vision for the Cancer Drugs Fund

Nina Pinwill, National Lead for the Cancer Drugs Fund
Cancer52 All Members Meeting

Tuesday 24th January 2017

Overview

1. Background
2. What do the changes mean?
3. How did we get here?
4. How does it work? Process and money.
5. Outputs so far
6. Treatments for rare & less common cancers

Appraisal and Funding of Cancer Drugs
from July 2016 (including the new
Cancer Drugs Fund)

A new deal for patients, taxpayers and
industry



1. Background

Urgent need for reform

- Temporary solution in 2011
- Bridge to Value Based Pricing (defunct)
- Whilst 95,000 people benefitted it constantly overspent

National scrutiny and political & stakeholder pressure

- Independent Cancer Taskforce Report (July 2015)
- Public Accounts Committee Report (Jan 2016)

Reformed (29th July 2016)

- Consultation
- Fundamental change to 'new' CDF; now linked to NICE decision making

2. What do the changes mean?


Three key objectives:

- Firstly, patients have faster access to the most promising new cancer treatments.
- Secondly, taxpayers get better value for money in drug expenditure.
- Thirdly, pharmaceutical companies that are willing to price their products responsibly can access a new, fast-track route to NHS funding for the best and most promising drugs.

3. How we got here....


- NHS England and NICE ran a joint, 12-week public consultation on our proposals between November 2015 and February 2016.
- We received more than 300 responses to consultation.
- NHS England and NICE Boards approved the proposals the Spring of 2016.
- Extensive engagement subsequently with patient groups and industry on the development of the operational detail.
- New Standard Operating Procedure published on 8th July 2016.
- New process went 'live' on 29th July 2016.

4. How does it work? Process:



4. How does it work? Money:

- Fixed annual budget £340m in 2016/17 and 2017/18



**Interim funding, Managed
Access Agreements,
transition drugs, existing
commitments, CDF
administration**

The expenditure control mechanism ensures the CDF budget does not overspend.


5. Outputs so far

- Regularly updated [National Cancer Drugs Fund List](#) on NHS England's website

Positive NICE guidance - routine NHS England funding	12	drug(s) in	12	indications
Negative NICE guidance	0	drug(s) in	0	indications
Rejection by manufacturer of transition funding	2	drug(s) in	2	indications
Transition Drugs	19	drug(s) in	31	indications
Drugs receiving CDF interim funding	7	drug(s) in	10	indications
Drugs receiving CDF funding	1	drug(s) in	1	indications
TOTAL	25	drug(s) in	42	indications
Off-label indications	4	drug(s) in	9	indications
Licensed indications	22	drug(s) in	33	indications

*a single drug can have more than one indication and so be counted in each category

6. Treatments for rare & less common cancers

- Now NICE appraising every cancer drug and lots of rarer cancers getting positive recommendations and funding in the last 9 months:
 - ✓ CML: dasatinib has 3 indications; bosutinib
 - ✓ Ibrutinib has 2 indications in CLL
 - ✓ Pomalidomide & panobinostat for myeloma
 - ✓ For melanoma dabrafenib & trametinib combo, talimogene, ipilimumab & nivolumab combo
 - ✓ Nivolumab in kidney cancer
 - ✓ Olaparib in ovarian cancer
-  5 drug indications under consideration for CDF evaluation

Questions?